Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management. Its portfolio includes two products. Adlea, a long-acting, site-specific, non-opioid analgesic, is being developed for moderate to severe pain, and has completed multiple Phase II trials in post-surgical, musculoskeletal and neuropathic pain and Phase III trials in bunionectomy and total knee arthroplasty (TKA, or total knee replacement surgery). The Company is initially pursuing an indication for Adlea for the management of acute pain associated with orthopedic surgeries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the Food and Drug Administration (FDA) in August 2007, to reduce the pain associated with peripheral intravenous (IV) insertions or blood draws in children 3 to 18 years of age. Zingo was approved in January 2009, to reduce the pain associated with blood draws in adults.

Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. Elusys Therapeutics company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim has shown to be effective in combatting infections caused by anthrax up to 48 hours after exposure. When administered prior to exposure, the drug has proven to be 100% effective in preventing infections. Another drug candidate, Staph A Heteropolymer, targets staphylococcus infections, which have become increasingly prevalent and resistent to treatment. Other Elusys products target non-Hodgkin's lymphomas, lupus, and deep vein thrombosis.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

A. Nelson & Co. is Europe's oldest and the UK's largest manufacturer of homeopathic medicines and other natural healthcare products. Its homeopathic creams, ointments, sprays, and tablets treat a range of health problems from common colds to skin conditions. Its formulated remedies include Travella for travel sickness, Teetha for teething discomfort, Coldenza for cold and flu symptoms, Noctura for insomnia, and Pollenna for hay fever. The company is the manufacturer of Bach floral remedies, including the popular Rescue Remedy. Nelson distributes its products worldwide and operates specialized manufacturing labs in the UK. The company is owned by the Wilson family.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Sirtris Pharmaceuticals can help keep you healthy in your golden years. The biopharmaceutical company focuses on developing drugs for treating ailments of aging. Its trial drug for the treatment of Type 2 Diabetes, which is associated with obesity, provides health benefits similar to calorie restriction without a change in diet. Founded in 2004, the company owns or licenses more than 150 patent applications for sirtuins, a class of enzymes. The activation of sirtuins helps reduce weight gain, as well improve glucose levels and insulin sensitivity. Sirtris filed an IPO in 2007, but was then acquired by GlaxoSmithKline (GSK) the following year.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.